Grünenthal Gmbh opposition analysis

COMPANY ANALYSIS

Latest patents of Grünenthal Gmbh opposed by its competitors

Patent:
Grant Date:
Jul 13, 2022
Title:
Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt
Oppositions:
2
Patent:
Grant Date:
Nov 17, 2021
Title:
Process For The Preparation Of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol
Oppositions:
3
Patent:
Grant Date:
Apr 14, 2021
Title:
Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol
Oppositions:
6
Patent:
Grant Date:
Jul 22, 2020
Title:
(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful Inflammations
Oppositions:
4
Patent:
Grant Date:
Apr 22, 2020
Title:
Aqueous Pharmaceutical Formulation Of Tapentadol For Oral Administration
Oppositions:
1
Patent:
Grant Date:
Oct 2, 2019
Title:
Tapentadol For Treating Pain Associated With Trigeminal Neuralgia
Oppositions:
1
Patent:
Grant Date:
Oct 31, 2018
Title:
Tapentadol For Preventing Chronification Of Pain
Oppositions:
3
Patent:
Grant Date:
Mar 22, 2017
Title:
Break-Resistant Delayed-Release Forms Of Administration
Oppositions:
1

Competitors of Grünenthal Gmbh

G. L. PHARMA GMBH

HEXAL AG

INSUD PHARMA SL

Want to track Grünenthal Gmbh?

Feel free to send us a message here and we will get back to you